A study of preclinical mouse models for gastrointestinal cancers demonstrated that bazedoxifene displays anticancer activity by reducing the GC tumour burden in gp130Y757F mice, whereas tumours arise through glycoprotein 130 (gp130)/ signal transducer and activator of transcription 3 (STAT3) signalling in response to the Interleukin-6 (IL-6) family cytokine IL-11 [158]. This evidence concerns the gene IL6 and neoplasm.